Mackintosh J F, Cowan R A, Jones M, Harris M, Deakin D P, Crowther D
CRC Department of Medical Oncology, Christie Hospital and Holt Radium Institute, Manchester, U.K.
Eur J Cancer Clin Oncol. 1988 Oct;24(10):1617-22. doi: 10.1016/0277-5379(88)90054-5.
Between 1975 and 1986, the Manchester Lymphoma Group treated 127 patients with localized (Stages I/II) high and intermediate grade non-Hodgkin's lymphoma (NHL) on one of three protocols of combined involved field radiotherapy and chemotherapy. The study included patients with widespread bulky abdominal disease providing there was no apparent spread outside the abdomen and the liver was not involved with metastatic disease. The median duration of follow-up was 70 months. The complete response rate was 86% and the overall 5-year survival was 70%. The 5-year relapse-free survival of the complete responders was 80%. Cox model multivariate analysis showed that bulk disease (greater than 5 cm), low serum albumin and gut involvement were the pretreatment factors associated with shorter survival. When remission status was included in the model the attainment of a complete response was the major determinant of long-term survival but bulk disease and gut involvement were still significant adverse predictors for survival. These factors need to be assessed when analysing results of therapy in NHL and in the design of future treatment strategies.
1975年至1986年间,曼彻斯特淋巴瘤研究小组采用三种联合累及野放疗和化疗方案之一,对127例局限性(I/II期)高中度非霍奇金淋巴瘤(NHL)患者进行了治疗。该研究纳入了腹部有广泛大块病灶的患者,前提是腹部以外无明显扩散且肝脏未发生转移性病变。随访的中位时间为70个月。完全缓解率为86%,总体5年生存率为70%。完全缓解者的5年无复发生存率为80%。Cox模型多因素分析显示,大块病灶(大于5 cm)、低血清白蛋白和肠道受累是与生存期较短相关的预处理因素。当将缓解状态纳入模型时,获得完全缓解是长期生存的主要决定因素,但大块病灶和肠道受累仍然是生存的显著不良预测因素。在分析NHL治疗结果和设计未来治疗策略时,需要评估这些因素。